This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
The meeting, which helps the FDA give guidance to vaccine makers on which flu st...
Verve offered few details on the early end of a collaboration the companies inke...
While announcing billions of dollars in new U.S. investments, company chief Davi...
The British drugmaker claimed study success in a first-line setting in breast ca...
The company is doubling plans for capital spending on U.S. factories as Presiden...
The funding comes as Eikon, run by former Merck research chief Roger Perlmutter,...
Telehealth provider Hims & Hers said it will tell consumers they need to seek “a...
Ten of 11 children born with a rare form of congenital hearing loss experienced ...
The Trump administration’s plans to reduce National Institutes of Health grant f...
An industry source said “most, if not all” of the people at CDRH who were recent...
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug con...
Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendi...
Cavazzoni stepped down from her role as head of the FDA’s main drug review offic...
Detailed results presented at a medical congress help reinforce analyst expectat...
Early-phase clinical trials, including phase 1 and some phase 2a studies, serve ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer...
Pfizer’s decision to halt further marketing of Beqvez is further sign of the spa...
The pioneering gene therapy developer will be acquired by investment firms Carly...
Originally scheduled for next week, the meeting of agency advisers will be delay...
Layoffs at the FDA’s device center could add “months, if not years” to the time ...
"Any place that gets cut, it's going to have an impact, because there's not any ...
Scott Whitaker sent a letter to HHS calling for staff cuts at the FDA to be reve...
A Missouri district court judge said stopping the FTC’s suit against Caremark, E...
The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foot...